Endorectal MRI foretells prostate cancer prognosis

Article

Researchers have found that endorectal MRI can accurately predict recurrence and development of metastatic disease in patients about to undergo radiation therapy for prostate cancer. Study findings suggest a stronger management role for MRI.

Researchers have found that endorectal MRI can accurately predict recurrence and development of metastatic disease in patients about to undergo radiation therapy for prostate cancer. Study findings suggest a stronger management role for MRI.

Dr. Fergus V. Coakley, a professor of radiology and urology at the University of California, San Francisco, and colleagues retrospectively analyzed images from 80 men with prostate cancer who had an MR scan before undergoing external-beam radiation therapy. The investigators recorded tumor findings, treatment, and outcomes and used regression analysis to correlate survival with specific characteristics of prostate disease. They found that MRI could accurately predict post-treatment recurrence and disease spread based on the presence and degree of extracapsular extension (Radiology 2008;247:141-146).

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.